Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2008

View Archived Issues

Escitalopram effective in treating multisomatoform disorder

NK-012 evaluated in phase I study in advanced cancer patients

Ki-20227 shows rheumatoid arthritis treatment potential in vivo

Recent patents describe new treatments for cardiovascular disorders

New therapeutic agents for genitourinary disorders reported in recent Roche patent

Florida International University patent discloses novel free radical scavengers

Otsuka and OncoTherapy Science enter license agreement for pancreatic cancer vaccine

Exercise-induced NMDA receptor activity prevents mature motor unit death in SMA

Bone Medical reports positive data from second clinical trial of CaPTHymone for osteoporosis

Epix reaches agreement with FDA for resubmission of Vasovist NDA

Solvay submits complete response to FDA approvable letter for Luvox CR

Eisai temporarily withdraws Japanese application for Pariet to conduct additional study

European Commission approves Novartis' Galvus as oral treatment for type 2 diabetes

Auris Medical completes patient enrollment in phase I/II trial with AM-101

Glenmark to get back global rights to melogliptin from Merck Serono

Pipex to meet with FDA following non acceptance of Coprexa NDA

Asmanex Twisthaler approved for asthma maintenance treatment in children

FDA grants orphan drug designation to VQD-002 in multiple myeloma

EU Commission grants broad approval of Xeloda in metastatic colorectal cancer

FDA approves Endeavor zotarolimus-eluting stent for clogged arteries

BioLineRx reports positive results from phase IIa BL-1020 trial in schizophrenia

Genzyme and Isis granted Hart-Scott-Rodino clearance for collaboration agreeement

First patient dosed in phase II trial of AGI-004 in chemotherapy-induced diarrhea

MedImmune submits BLA for motavizumab in the U.S.

EMEA grants positive opinion for GSK's Hycamtin in relapsed SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...